We Manufacture Products That Change Lives™
Life changing perinatal tissue allografts based on our proprietary BioREtain® process.
Best-In-Class Perinatal Tissue Allografts
- BioStem Technologies® produces innovative perinatal tissue-based allografts.
- Our membrane allografts are manufactured using our proprietary BioREtain® processing method that preserves the quality of the tissue.
- In our AATB® accredited, FDA® registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
Best-In-Class Perinatal Tissue Allografts
- BioStem Technologies® produces innovative perinatal tissue-based allografts.
- Our membrane allografts are processed using our proprietary BioREtain® processing method that preserves the biologic quality of the tissue.
- In our AATB® accredited, FDA® registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
Why Choose Us
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
Our allografts are processed utilizing our proprietary BioREtain® method, which focuses on preserving the tissue’s endogenous biological properties while maintaining the structure and matrix found in fresh perinatal tissue.
BioStem is committed to improving patients’ quality of life through scientific innovation and strict adherence to our quality system.
Latest News
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) —BioStem Technologies, Inc.(OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces the initiation of the BR-AM-DFU (BioREtain®Amniotic Membrane – Diabetic Foot Ulcers) clinical trial to evaluateVendaje®versus standard of care for patients suffering with non-healing…
Subscribe To Our Newsletter
To stay up to date on all of our news, products, and achievements, please subscribe to our newsletter.